FY2024 Earnings Estimate for Exagen Issued By William Blair

Exagen Inc. (NASDAQ:XGN) – Equities researchers at William Blair raised their FY2024 EPS estimates for shares of Exagen in a research note issued on Wednesday, November 13th. William Blair analyst A. Brackmann now forecasts that the company will post earnings per share of ($0.89) for the year, up from their prior estimate of ($0.94). William Blair has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.87) per share. William Blair also issued estimates for Exagen’s Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.70) EPS.

Exagen Stock Performance

Shares of NASDAQ XGN opened at $3.53 on Monday. The business has a fifty day simple moving average of $2.83 and a 200 day simple moving average of $2.43. The firm has a market capitalization of $62.26 million, a price-to-earnings ratio of -3.76 and a beta of 1.35. Exagen has a one year low of $1.30 and a one year high of $3.71. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 1.54.

Exagen (NASDAQ:XGN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The firm had revenue of $12.51 million during the quarter, compared to the consensus estimate of $13.55 million. During the same period in the prior year, the firm earned ($0.31) EPS.

Insider Activity at Exagen

In other news, CEO John Aballi acquired 24,305 shares of the firm’s stock in a transaction on Thursday, November 14th. The shares were purchased at an average cost of $2.81 per share, with a total value of $68,297.05. Following the completion of the purchase, the chief executive officer now owns 689,799 shares of the company’s stock, valued at $1,938,335.19. This represents a 3.65 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 26.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Exagen

A number of large investors have recently bought and sold shares of the business. Stonepine Capital Management LLC grew its holdings in Exagen by 49.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after acquiring an additional 175,701 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Exagen by 93.3% during the second quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock worth $172,000 after purchasing an additional 45,476 shares in the last quarter. Palumbo Wealth Management LLC grew its stake in shares of Exagen by 14.5% during the third quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company’s stock valued at $236,000 after purchasing an additional 9,695 shares during the last quarter. Creative Planning acquired a new stake in shares of Exagen in the third quarter valued at approximately $110,000. Finally, Verus Capital Partners LLC bought a new position in Exagen in the 3rd quarter worth approximately $39,000. 75.25% of the stock is currently owned by institutional investors.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).